NOL3

NOL3 is a dual-function protein that originated in the literature as a nuclear/nucleolar splicing modulator and was subsequently established as an anti-apoptotic regulator and context-dependent tumor suppressor (PMID:10196175, PMID:28232469). The gene produces two isoforms by alternative 5' splice site usage: a serine/arginine-rich C-terminal form targeted to the nucleus/nucleolus and a proline/glutamic acid-rich form that is predominantly cytosolic (PMID:10196175). The nuclear form multimerizes and binds specifically the RS domain of the splicing factor SRp30c, and its overexpression shifts alternative exon usage in reporter genes, defining a role in alternative splice site selection (PMID:10196175). In cells subjected to oxidative stress, NOL3 protects against apoptosis by limiting ROS production, mitochondrial depolarization, and DNA fragmentation while modulating Bax/Bcl-2, caspase-2/-3/-8, PARP, and p53 signaling (PMID:27221790). In the myeloid compartment NOL3 acts as a tumor suppressor: its loss in mice drives a myeloproliferative neoplasm resembling primary myelofibrosis through stem cell expansion, JAK-STAT activation, and downstream CDK6 and Myc induction (PMID:28232469). NOL3 expression is transcriptionally controlled, being repressed by ATXN1L/HDAC3-mediated histone H3 deacetylation at its promoter and induced by ELK1; ELK1-driven NOL3 binds GRP78 to activate the PERK/CHOP arm of the unfolded protein response and promote proliferation and stemness in TP53-mutant colon cancer cells (PMID:35414011, PMID:41864308). A cosegregating NOL3 mutation that alters the protein's post-translational modification has been linked to familial cortical myoclonus (PMID:22926851).

1. 1999 Medium

   Established that NOL3 is produced as two isoforms with distinct C-termini and localizations, defining how a single gene generates nuclear/nucleolar versus cytosolic protein pools.

   Evidence Alternative splicing characterization and subcellular localization studies

   PMID:10196175

   Open questions at the time

   • Functional consequences of the two isoforms not separately dissected
   • No determination of which isoform predominates in different tissues
2. 1999 High

   Answered what nuclear NOL3 binds by identifying a specific, multimerization-dependent interaction with the RS domain of SRp30c, placing NOL3 in the splicing machinery.

   Evidence Yeast two-hybrid, in vitro binding, and co-immunoprecipitation

   PMID:10196175

   Open questions at the time

   • Structural basis of RS-domain recognition not resolved
   • Whether the interaction occurs on assembled spliceosomes in vivo not shown
3. 1999 Medium

   Demonstrated functional consequence of NOL3 in splicing by showing overexpression alters alternative exon usage, linking the SRp30c interaction to splice site selection.

   Evidence Reporter gene overexpression assays (preprotachykinin, SRp20)

   PMID:10196175

   Open questions at the time

   • Endogenous splicing targets not defined
   • Direction of effect at native genes not mapped
4. 2012 Medium

   Connected NOL3 to human disease by identifying a cosegregating mutation in familial cortical myoclonus that alters the protein's post-translational modification.

   Evidence Mutation sequencing in a family plus in vitro PTM assay

   PMID:22926851

   Open questions at the time

   • Identity of the affected modification not detailed
   • Mechanistic link between altered PTM and neuronal phenotype not established
5. 2016 Medium

   Defined an anti-apoptotic, cytoprotective role by showing NOL3 protects neurons against oxidative-stress apoptosis and modulates mitochondrial and caspase signaling.

   Evidence Tat-NOL3 transduction into H2O2-exposed HT22 cells and a forebrain ischemia model with apoptotic-marker Western blots

   PMID:27221790

   Open questions at the time

   • Direct molecular targets among caspases/Bcl-2 family not identified
   • No mutagenesis to map the protective domain
6. 2017 High

   Established NOL3 as a myeloid tumor suppressor by showing its deletion causes a myeloproliferative neoplasm via stem cell expansion and JAK-STAT/CDK6/Myc activation.

   Evidence Nol3 knockout mouse with flow cytometry and pathway analysis

   PMID:28232469

   Open questions at the time

   • Direct biochemical step by which NOL3 restrains JAK-STAT not identified
   • Whether splicing or apoptotic function underlies suppression unresolved
7. 2022 Medium

   Revealed how NOL3 expression is set transcriptionally, showing ATXN1L recruits HDAC3 to deacetylate histone H3 and repress the NOL3 promoter.

   Evidence ChIP, HDAC3 inhibition, ATXN1L knockout, immunofluorescence and Western blot

   PMID:35414011

   Open questions at the time

   • Cellular context where this regulation dominates not generalized
   • Link between NOL3 repression and downstream phenotype not fully traced
8. 2026 Medium

   Connected NOL3 to ER-stress signaling by showing ELK1-induced NOL3 binds GRP78 to activate the PERK/CHOP UPR branch and promote proliferation/stemness in TP53-mutant cancer.

   Evidence Dual-luciferase reporter, co-IP, gain/loss-of-function studies, and xenografts

   PMID:41864308

   Open questions at the time

   • Structural basis and domain mediating GRP78 binding not defined
   • Reconciliation of pro-tumor UPR role with myeloid tumor-suppressor role not addressed

• How NOL3's splicing, anti-apoptotic, transcriptional-target, and UPR-modulating activities are integrated into one mechanistic model — and which isoform mediates each — remains unresolved.
• No structural model linking isoform/domain to each function
• Direct molecular substrates/targets in apoptosis and JAK-STAT suppression unidentified
• Apparent context-dependent opposing roles (tumor suppressor vs pro-tumor) not mechanistically reconciled